UBS lowered the firm’s price target on United Therapeutics (UTHR) to $385 from $410 and keeps a Buy rating on the shares. UBS sees favorable risk/reward on the stock from current valuation heading into the idiopathic pulmonary fibrosis read-out in Q3, which may be a significant binary clinical catalyst, and expects Tyvaso to benefit from a seasonally strong Q2 and Q3, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.